TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03551704

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT + EFT
Description: The CBT treatment will be implemented in 8-week group-based sessions (maximum 4 patients). Sessions will be carried out once a week over an 8-week period, with quit date occurring at fifth session. Patients will be asked to gradually reduce their nicotine intake (i.e., 25% each week). CBT components include: psychoeducation, self-monitoring, physiological feedback, training in stimulus control and strategies for controlling negative discomfort, and relapse prevention strategies.~As part of the EFT, participants will be asked to select future smoking-related events that would occur within the following time periods: 2 weeks, 1, and 6 months. They will be instructed to generate personal audio recordings that will be used to help them think about future decision-making choices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT + EFT + CM
Description: This intervention includes the abovementioned treatment components and a CM procedure reinforcing abstinence. This arm will consist on delivering CBT and EFT and providing patients incentives to promote and reinforce abstinence contingent on abstinence. The schedule will incorporate an increasing magnitude of reinforcement.
Study: NCT01974440

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bendamustine
Description: 90 milligram per meter square (mg/m\^2) administered intravenously on Days 1 to 2 of Cycles 1 to 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 milligram per meter square (mg/m\^2) administered intravenously on Days 1 to 2 of Cycles 1 to 6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
Study: NCT02731820

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 400 IU/die Vitamin D3 daily by mouth
Study: NCT01974440

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: 750 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
Study: NCT02731820

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium carbonate
Description: 500 mg/die calcium carbonate daily by mouth

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: 500 mg/die calcium carbonate daily by mouth
Study: NCT04624867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP-1050 Patch
Description: Both articles, HP-1050 and XULANE patch, will be applied simultaneously on the back of each subject.
Study: NCT03957668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG 3350
Description: PEG 3350 17 g once daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: Lactulose 10 g once daily for 14 days
Study: NCT01974440

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: 50 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vincristine
Description: 1.4 mg/m\^2 (maximum total 2 mg) administered intravenously on Day 1 of Cycles 1 to 6.
Study: NCT04804475

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Trainig
Description: SSE is performed on a thin exercise mat divided into 40 small squares in 250 cm x 100 cm of size (25 cm each part). Participants are given patterns of a few steps and asked to take steps that match them. Participants must, in principal, move ahead in line with the length forward with no contact on the lines forming the squares. Forward, backward, lateral and oblique stepping patterns are required. Stepping patterns get increasingly difficult. Each pattern consists of 2 to 16 steps; participants are asked to repeat step pattern till the end of exercise mat. Upon completing a pattern, another pattern in the same mirror-image is repeated. In essence each pattern is reiterated for 3-5 times and next its mirror-image pattern is repeated but if participants face challenge in performing the pattern it is repeated till the pattern is learnt
Study: NCT01104350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: external radiation therapy with gemcitabine
Description: All patients will undergo daily image-guided radiation therapy with concurrent twice weekly gemcitabine chemotherapy. Radiation therapy will begin 2-4 weeks after restaging cystoscopy/fiducial marker placement.~* Dose level #1: 23.4 Gy/1.8 Gy × 13 fractions (total dose 68.4 Gy)~* Dose level #2: 27.0 Gy/1.8 Gy × 15 fractions (total dose 72.0 Gy)~* Dose level #3: 30.6 Gy/1.8 Gy × 17 fractions (total dose 75.6 Gy)
Study: NCT00861172

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3T MR scanner
Description: The follow-up will be scheduled for one year; it will consist in a weekly MR examination during the first two months, and subsequently on the 6th and the 12th months.~We will perform for each MRI exploration an intravenous injection of contrast agents: gadobutrol (gadovist 1,0 mmol/ml) which is a stable agent with a cyclic structure. This agent is few responsible for NFS, given their low capacity to liberate gadolinium GD3+ in tissues.~The same imaging protocol will be performed for each MR examination. Evaluation of creatinemia will be used before inclusion and during the 1st, 3rd, 5th, 7th, 9th, and the 10th MRI examination. Thus we will take advantage of catheter to perform the creatinemia blood test and to reduce the discomfort produced by the injection.
Study: NCT01709617

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate ingestion
Description: Various types of carbohydrate ingested during and following exercise
Study: NCT00477893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: sc. injection Humira 40 mg every other week, from week 0 or 12 to the end of study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sc. inj. placebo every other week, week 0, 2, 4, 6, 8, and 10.
Study: NCT01235806

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI
Description: MRI of the scaphoid bone fracture suspicion
Study: NCT02494336

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-incisional rectus sheath block
Description: After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon. This will be done after closure of the fascial incision but prior to closure of the skin incision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic guided rectus sheath block
Description: After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered intra-abdominally under direct laparoscopic visualization into the rectus sheath bilaterally by the attending surgeon.
Study: NCT01709617

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion
Description: Various types of carbohydrate ingested during and following exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate ingestion
Description: Various types of carbohydrate ingested during and following exercise
Study: NCT04396548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine Oral Product
Description: Patients will receive oral 10 mg tablet of midodrine with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inert tablet containing sugar (placebo)
Description: : Patients will receive Inert tablet containing sugar (placebo) with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine
Study: NCT03818607

Intervention type: DRUG
Group type: OTHER
Intervention: ABP 959
Description: intravenous infusion

Intervention type: DRUG
Group type: OTHER
Intervention: ABP 959
Description: intravenous infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Eculizumab
Description: intravenous infusion
Study: NCT00850668

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3
Description: Up to 7 mL solution administered rectally
Study: NCT03818607

Intervention type: DRUG
Group type: OTHER
Intervention: Eculizumab
Description: intravenous infusion
Study: NCT04539613

Intervention type: DRUG
Intervention: HPFSH & HMG
Description: . Various gonadotropin preparations
Study: NCT02494336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine is a long-acting local anesthetic. It has been shown to be effective for peripheral nerve, caudal, and lumbar/thoracic epidural blocks and produce less motor blockade than bupivacaine after caudal administration. It will be the local anesthetic used to perform the rectus sheath block for both arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine is a long-acting local anesthetic. It has been shown to be effective for peripheral nerve, caudal, and lumbar/thoracic epidural blocks and produce less motor blockade than bupivacaine after caudal administration. It will be the local anesthetic used to perform the rectus sheath block for both arms.
Study: NCT03560102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips Sonalleve® MR-HIFU Breast Therapy System
Description: The breast tumor lesion of qualified study patients will be treated with MR-HIFU under procedural sedation with Propofol and Ketamine.
Study: NCT03707990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0165-1875
Description: Participants will receive a single dose of subcutaneous (s.c.) NNC0165-1875 injection. The planned doses of NNC0165-1875 are as following: cohort 1 and 7: 0.1 mg, cohort 2 and 8: 0.3 mg, cohort 3 and 9: 0.6 mg, cohort 4 and 10: 1.2 mg, cohort 5 and 11: 2.4 mg and cohort 6: 0.03 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0165-1875)
Description: Participants will receive a single dose of s.c. placebo injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive a single dose of s.c. semaglutide 0.25 mg injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide
Description: Participants will receive a single dose of s.c. semaglutide 0.25 mg injection.
Study: NCT00641238

Intervention type: DEVICE
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation
Study: NCT02173639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356/metformin
Description: fixed dose combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT04790669

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Daily adjustable progressive resistance exercises (DAPRE)
Description: Daily adjustable progressive resistance exercises (DAPRE) In Group A, 11 participants were received Conventional physiotherapy treatment in addition to DAPRE technique by leg extension machine. In DAPRE technique, four sets of exercises were performed. The first two sets of exercise consisted of ten and then six repetitions, per- formed against one-half and three-fourths of the previously established working weight. Working weight is the amount of weight a patient uses during an individual session. The full working weight was used on the third set, and the patient performed as many repetitions as possible. After performing each of the third and fourth sets, patients rested for 1 min.6 weeks (3 sessions per week)• Hot pack: 10 min• Stretching of calf and hamstring muscle: 10 min. Assessment was done via WOMAC index, universal goniometer, numeric pain rating scale \& sphygmomanometer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Close kinetic chain exercises (CKC).
Description: Close kinetic chain exercises (CKC). In Group B, 11 participants was received Conventional physiotherapy treatment in addition to close kinetic chain exercises. Close kinetic chain exercises for extensor lag was seated leg press, double or single one third knee bend, step up and down exercise, wall slide with weight. Treatment time was 30 minutes and three session per week was applied on alternate day for up to 6 weeks. Pre interventional readings will be taken at baseline \& post interventional readings at 6th week. 6 weeks (3 sessions per week) • Hot pack: 10 min • Stretching of calf and hamstring muscle: 10 min. Assessment was done via WOMAC index, universal goniometer, numeric pain rating scale \& sphygmomanometer.
Study: NCT00436046

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent inactivated influenza virus vaccine (2006-2007 formulation)
Description: Commercially available trivalent inactivated influenza virus vaccine without or with 1 of 2 dosages of commercially available type 1 interferon administered once by nasal instillation. Dosages: 0.6 ml of IVV or 0.7 ml of IVV.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza virus vaccine (2006-2007 formulation)
Description: Commercially available trivalent inactivated influenza virus vaccine without or with 1 of 2 dosages of commercially available type 1 interferon administered once by nasal instillation. Dosages: 0.6 ml of IVV or 0.7 ml of IVV.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza virus vaccine (2006-2007 formulation)
Description: Commercially available trivalent inactivated influenza virus vaccine without or with 1 of 2 dosages of commercially available type 1 interferon administered once by nasal instillation. Dosages: 0.6 ml of IVV or 0.7 ml of IVV.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Type 1 interferon
Description: Commercially available lyophilized IFN; dosages 1 M unit (Mu) of IFN; 10 M units (Mu) of IFN.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Type 1 interferon
Description: Commercially available lyophilized IFN; dosages 1 M unit (Mu) of IFN; 10 M units (Mu) of IFN.
Study: NCT02406924

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: A cylinder of grafted bone will be removed from the location elected for the implant installation with an appropriate trephine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: A cylinder of grafted bone will be removed from the location elected for the implant installation with an appropriate trephine

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Tomography
Description: An initial computerized tomography will be made before the first surgery, and a final computerized tomography will be made after 9 months, previously to the second surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computerized Tomography
Description: An initial computerized tomography will be made before the first surgery, and a final computerized tomography will be made after 9 months, previously to the second surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized periapical radiographs
Description: A device will be adopted for the standardization, and radiographs will be taken at day 0, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoral scanning
Description: Intraoral scanning will be made before the graft, at implant installation, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
Study: NCT00624468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to atacicept
Description: Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
Study: NCT03520920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered zanubrutinib 160 mg orally (PO) BID continuously
Study: NCT01974440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m\^2 (maximum total 2 mg) administered intravenously on Day 1 of Cycles 1 to 6.
Study: NCT00850668

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3
Description: Up to 7 mL solution administered rectally
Study: NCT04305483

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Bleaching
Description: Content; There are 35% hydrogen peroxide, potassium nitrate, sodium fluoride, sodium hydroxide, thickener, glycol derivative. The way of application; Gingival protection is applied. The gel is applied to the labial surfaces of the teeth with a thickness of 1-2 mm. The use of laser increases the effectiveness of the gel. Operator and patient use protective glasses during laser application. The gel shows its effectiveness in about eight minutes. Then the gel is removed with the help of saliva absorber. The procedure is repeated until the desired degree of whitening is achieved. Then it is checked with a color scale.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chemical Bleaching
Description: Total Blanc Office Teeth Whitening System (H35) will be used as chemical whitening agent. Content; There are 35% hydrogen peroxide, thickener, plant extracts, amide, release agent, glycol, paint and water. Method of Application; Gingival protection is applied. A 1 mm thick layer of gel is applied to all of the labial surfaces of the tooth. The whitening agent remains on the tooth surface for 20 minutes. At the end of this period, the gel is removed with saliva absorber and the surface is cleaned with a moist gauze.
Study: NCT03724955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol 2 mg
Description: Participants in this arm will receive Estradiol 2 mg oral daily for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive placebo oral daily for 6 months
Study: NCT03520920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered zanubrutinib 160 mg orally (PO) BID continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered rituximab 375 mg/m\^2 intravenously on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered rituximab 375 mg/m\^2 intravenously on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.
Study: NCT04457791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized dietary advice
Description: Via an self-developed website and algorithm, participants will receive digital personalized dietary advice to increase dietary fiber intake, aiming to reduce constipation complaints. The advice is personalized on phenotype (habitual diet, gender)
Study: NCT03309254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Glycemic Index
Description: High Glycemic Index Food
Study: NCT01974440

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: 100 mg administered orally on Days 1 to 5 of Cycles 1 to 6.
Study: NCT03309254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index
Description: Low Glycemic Index Food
Study: NCT01032408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Focetria®
Description: 7.5 ug of HA antigen; adjuvanted; monovalent
Study: NCT01974440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg administered orally on Days 1 to 5 of Cycles 1 to 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765 (Ibrutinib)
Description: 560 mg (4\*140 mg) capsules administered orally once daily, continuously starting on Cycle 1, Day 1.
Study: NCT02397759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw and cerebrospinal fluid draw

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw and cerebrospinal fluid draw
Study: NCT01974440

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (4 capsules) matched to ibrutinib administered orally once daily, continuously starting on Cycle 1, Day 1.
Study: NCT02397759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw and cerebrospinal fluid draw
Study: NCT00704054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: Ridaforolimus is given as an IV infusion over 30 minutes on days 1-5 and 15-19 of each 28 day cycle. For children less than 10 kg body weight, dosing will be adjusted.
Study: NCT01880840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 205.5 mcg of azelastine hydrochloride
Description: nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 137 mcg of azelastine hydrochloride
Description: nasal spray
Study: NCT03276156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib plus S-1
Description: Drug:Apatinib (425 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (500 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (675mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (750 mg/d) + S-1 (80mg to 120 mg);